U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07944482) titled 'A Study on the Pharmacokinetics and Safety of GST-HG141 Tablets in Participants With Hepatic Impairment and Normal Liver Function' on Nov. 09.

Brief Summary: This is a multicenter, non-randomized, open-label, parallel-group, single-dose study designed to evaluate the pharmacokinetic profiles and safety of GST-HG141 tablets in participants with hepatic impairment.

Study Start Date: July 03

Study Type: INTERVENTIONAL

Condition: Chronic Hepatitis b

Intervention: DRUG: GST-HG141

GST-HG141 will be administered as a single oral dose on the morning of day 1

Recruitment Status: RECRUITING

Sponsor: Fujian Akeylink Biotechnology Co.,...